A citation-based method for searching scientific literature

Kausik K Ray, Ulf Landmesser, Lawrence A Leiter, David Kallend, Robert Dufour, Mahir Karakas, Tim Hall, Roland P T Troquay, Traci Turner, Frank L J Visseren, Peter Wijngaard, R Scott Wright, John J P Kastelein. N Engl J Med 2017
Times Cited: 447







List of co-cited articles
906 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Marc S Sabatine, Robert P Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D Wiviott, Sabina A Murphy, Julia F Kuder, Huei Wang, Thomas Liu, Scott M Wasserman,[...]. N Engl J Med 2017
39

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Kausik K Ray, R Scott Wright, David Kallend, Wolfgang Koenig, Lawrence A Leiter, Frederick J Raal, Jenna A Bisch, Tara Richardson, Mark Jaros, Peter L J Wijngaard,[...]. N Engl J Med 2020
277
39

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington,[...]. N Engl J Med 2018
33

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.
Kevin Fitzgerald, Suellen White, Anna Borodovsky, Brian R Bettencourt, Andrew Strahs, Valerie Clausen, Peter Wijngaard, Jay D Horton, Jorg Taubel, Ashley Brooks,[...]. N Engl J Med 2017
372
29

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference,[...]. Eur Heart J 2020
27

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
Frederick J Raal, David Kallend, Kausik K Ray, Traci Turner, Wolfgang Koenig, R Scott Wright, Peter L J Wijngaard, Danielle Curcio, Mark J Jaros, Lawrence A Leiter,[...]. N Engl J Med 2020
182
26

Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing.
Jayaprakash K Nair, Jennifer L S Willoughby, Amy Chan, Klaus Charisse, Md Rowshon Alam, Qianfan Wang, Menno Hoekstra, Pachamuthu Kandasamy, Alexander V Kel'in, Stuart Milstein,[...]. J Am Chem Soc 2014
530
21

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
20

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
Jonathan C Cohen, Eric Boerwinkle, Thomas H Mosley, Helen H Hobbs. N Engl J Med 2006
19

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Jennifer G Robinson, Michel Farnier, Michel Krempf, Jean Bergeron, Gérald Luc, Maurizio Averna, Erik S Stroes, Gisle Langslet, Frederick J Raal, Mahfouz El Shahawy,[...]. N Engl J Med 2015
18

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
Brian A Ference, Henry N Ginsberg, Ian Graham, Kausik K Ray, Chris J Packard, Eric Bruckert, Robert A Hegele, Ronald M Krauss, Frederick J Raal, Heribert Schunkert,[...]. Eur Heart J 2017
17

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
Marianne Abifadel, Mathilde Varret, Jean-Pierre Rabès, Delphine Allard, Khadija Ouguerram, Martine Devillers, Corinne Cruaud, Suzanne Benjannet, Louise Wickham, Danièle Erlich,[...]. Nat Genet 2003
17

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
Kausik K Ray, Harold E Bays, Alberico L Catapano, Narendra D Lalwani, LeAnne T Bloedon, Lulu R Sterling, Paula L Robinson, Christie M Ballantyne. N Engl J Med 2019
249
16

GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.
Aaron D Springer, Steven F Dowdy. Nucleic Acid Ther 2018
188
16

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
Marc S Sabatine, Robert P Giugliano, Stephen D Wiviott, Frederick J Raal, Dirk J Blom, Jennifer Robinson, Christie M Ballantyne, Ransi Somaratne, Jason Legg, Scott M Wasserman,[...]. N Engl J Med 2015
15

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.
Kevin Fitzgerald, Maria Frank-Kamenetsky, Svetlana Shulga-Morskaya, Abigail Liebow, Brian R Bettencourt, Jessica E Sutherland, Renta M Hutabarat, Valerie A Clausen, Verena Karsten, Jeffrey Cehelsky,[...]. Lancet 2014
385
14

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
Mark J Graham, Richard G Lee, Teresa A Brandt, Li-Jung Tai, Wuxia Fu, Raechel Peralta, Rosie Yu, Eunju Hurh, Erika Paz, Bradley W McEvoy,[...]. N Engl J Med 2017
338
14

Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial.
Kausik K Ray, Robert M Stoekenbroek, David Kallend, Toshiyuki Nishikido, Lawrence A Leiter, Ulf Landmesser, R Scott Wright, Peter L J Wijngaard, John J P Kastelein. JAMA Cardiol 2019
53
24

Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies.
R Scott Wright, Michael G Collins, Robert M Stoekenbroek, Richard Robson, Peter L J Wijngaard, Ulf Landmesser, Lawrence A Leiter, John J P Kastelein, Kausik K Ray, David Kallend. Mayo Clin Proc 2020
40
32

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
C Baigent, L Blackwell, J Emberson, L E Holland, C Reith, N Bhala, R Peto, E H Barnes, A Keech, J Simes,[...]. Lancet 2010
12

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
David Adams, Alejandra Gonzalez-Duarte, William D O'Riordan, Chih-Chao Yang, Mitsuharu Ueda, Arnt V Kristen, Ivailo Tournev, Hartmut H Schmidt, Teresa Coelho, John L Berk,[...]. N Engl J Med 2018
12

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates.
Maria Frank-Kamenetsky, Aldo Grefhorst, Norma N Anderson, Timothy S Racie, Birgit Bramlage, Akin Akinc, David Butler, Klaus Charisse, Robert Dorkin, Yupeng Fan,[...]. Proc Natl Acad Sci U S A 2008
451
12

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.
Sotirios Tsimikas, Ewa Karwatowska-Prokopczuk, Ioanna Gouni-Berthold, Jean-Claude Tardif, Seth J Baum, Elizabeth Steinhagen-Thiessen, Michael D Shapiro, Erik S Stroes, Patrick M Moriarty, Børge G Nordestgaard,[...]. N Engl J Med 2020
270
12

Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
Anne C Goldberg, Lawrence A Leiter, Erik S G Stroes, Seth J Baum, Jeffrey C Hanselman, LeAnne T Bloedon, Narendra D Lalwani, Pragna M Patel, Xin Zhao, P Barton Duell. JAMA 2019
153
11

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
Michelle L O'Donoghue, Sergio Fazio, Robert P Giugliano, Erik S G Stroes, Estella Kanevsky, Ioanna Gouni-Berthold, KyungAh Im, Armando Lira Pineda, Scott M Wasserman, Richard Češka,[...]. Circulation 2019
287
11

Evinacumab for Homozygous Familial Hypercholesterolemia.
Frederick J Raal, Robert S Rosenson, Laurens F Reeskamp, G Kees Hovingh, John J P Kastelein, Paolo Rubba, Shazia Ali, Poulabi Banerjee, Kuo-Chen Chan, Daniel A Gipe,[...]. N Engl J Med 2020
173
11

Cognitive Function in a Randomized Trial of Evolocumab.
Robert P Giugliano, François Mach, Kenton Zavitz, Christopher Kurtz, Kyungah Im, Estella Kanevsky, Jingjing Schneider, Huei Wang, Anthony Keech, Terje R Pedersen,[...]. N Engl J Med 2017
251
10

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
Paul M Ridker, James Revkin, Pierre Amarenco, Robert Brunell, Madelyn Curto, Fernando Civeira, Marcus Flather, Robert J Glynn, Jean Gregoire, J Wouter Jukema,[...]. N Engl J Med 2017
381
10

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
B Mihaylova, J Emberson, L Blackwell, A Keech, J Simes, E H Barnes, M Voysey, A Gray, R Collins, C Baigent. Lancet 2012
10

Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.
Ulrich Laufs, Maciej Banach, G B John Mancini, Daniel Gaudet, LeAnne T Bloedon, Lulu Ren Sterling, Stephanie Kelly, Erik S G Stroes. J Am Heart Assoc 2019
142
10

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.
Frederick E Dewey, Viktoria Gusarova, Richard L Dunbar, Colm O'Dushlaine, Claudia Schurmann, Omri Gottesman, Shane McCarthy, Cristopher V Van Hout, Shannon Bruse, Hayes M Dansky,[...]. N Engl J Med 2017
414
10

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.
Joseph L Witztum, Daniel Gaudet, Steven D Freedman, Veronica J Alexander, Andres Digenio, Karren R Williams, Qingqing Yang, Steven G Hughes, Richard S Geary, Marcello Arca,[...]. N Engl J Med 2019
183
10

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Deepak L Bhatt, P Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. N Engl J Med 2019
10

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation.
Nabil G Seidah, Suzanne Benjannet, Louise Wickham, Jadwiga Marcinkiewicz, Stephanie Belanger Jasmin, Stefano Stifani, Ajoy Basak, Annik Prat, Michel Chretien. Proc Natl Acad Sci U S A 2003
817
9

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Paul M Ridker, Brendan M Everett, Tom Thuren, Jean G MacFadyen, William H Chang, Christie Ballantyne, Francisco Fonseca, Jose Nicolau, Wolfgang Koenig, Stefan D Anker,[...]. N Engl J Med 2017
9

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.
Jonathan Cohen, Alexander Pertsemlidis, Ingrid K Kotowski, Randall Graham, Christine Kim Garcia, Helen H Hobbs. Nat Genet 2005
910
9

Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial.
Lawrence A Leiter, Hwee Teoh, David Kallend, R Scott Wright, Ulf Landmesser, Peter L J Wijngaard, John J P Kastelein, Kausik K Ray. Diabetes Care 2019
38
23

Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
Christie M Ballantyne, Maciej Banach, G B John Mancini, Norman E Lepor, Jeffrey C Hanselman, Xin Zhao, Lawrence A Leiter. Atherosclerosis 2018
143
9

Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1.
Ulf Landmesser, Arash Haghikia, Lawrence A Leiter, R Scott Wright, David Kallend, Peter Wijngaard, Robert Stoekenbroek, John Jp Kastelein, Kausik K Ray. Cardiovasc Res 2021
23
39

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Nicholas J Viney, Julian C van Capelleveen, Richard S Geary, Shuting Xia, Joseph A Tami, Rosie Z Yu, Santica M Marcovina, Steven G Hughes, Mark J Graham, Rosanne M Crooke,[...]. Lancet 2016
422
9


N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.
Veronica J Alexander, Shuting Xia, Eunju Hurh, Steven G Hughes, Louis O'Dea, Richard S Geary, Joseph L Witztum, Sotirios Tsimikas. Eur Heart J 2019
97
9

Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
Manisha Balwani, Eliane Sardh, Paolo Ventura, Paula Aguilera Peiró, David C Rees, Ulrich Stölzel, D Montgomery Bissell, Herbert L Bonkovsky, Jerzy Windyga, Karl E Anderson,[...]. N Engl J Med 2020
154
9


RNA-Targeted Therapeutics.
Stanley T Crooke, Joseph L Witztum, C Frank Bennett, Brenda F Baker. Cell Metab 2018
324
9

Advances in oligonucleotide drug delivery.
Thomas C Roberts, Robert Langer, Matthew J A Wood. Nat Rev Drug Discov 2020
394
9

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.
A Fire, S Xu, M K Montgomery, S A Kostas, S E Driver, C C Mello. Nature 1998
9

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
Marc S Sabatine, Lawrence A Leiter, Stephen D Wiviott, Robert P Giugliano, Prakash Deedwania, Gaetano M De Ferrari, Sabina A Murphy, Julia F Kuder, Ioanna Gouni-Berthold, Basil S Lewis,[...]. Lancet Diabetes Endocrinol 2017
298
8

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Stephen J Nicholls, Rishi Puri, Todd Anderson, Christie M Ballantyne, Leslie Cho, John J P Kastelein, Wolfgang Koenig, Ransi Somaratne, Helina Kassahun, Jingyuan Yang,[...]. JAMA 2016
538
8

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
Kausik K Ray, Robert M Stoekenbroek, David Kallend, Lawrence A Leiter, Ulf Landmesser, R Scott Wright, Peter Wijngaard, John J P Kastelein. Circulation 2018
79
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.